Abstract Search

ea0029oc9.6 | Endocrine Tumours & Translation | ICEECE2012

First in vitro study of human gastroenteropancreatic-neuroendocrine tumors: comparative effect of octreotide and pasireotide

Mohamed A. , Blanchard M. , Albertelli M. , Niccoli P. , Monges G. , Garcia S. , Moutardier V. , Delpero J. , Enjalbert A. , Florio T. , Ferone D. , Saveanu A. , Barlier A.

Somatostatin analogs (SSAs) such as octreotide (OCT) are currently effective in controlling most hypersecretion associated symptoms of Gastoenteropancreatic-neuroendocrinetumors (GEP-NETs). The results of the phase IIIb PROMID trial showed that OCT doubled time to progression for patients with metastatic neuroendocrine midgut tumors compared with placebo. SSAs act on different intracellular pathways through different somatostatin receptor (Sst) subtypes. While OCT is mainly an...

0 shares

Endocrine Abstracts

First in vitro study of human gastroenteropancreatic-neuroendocrine tumors: comparative effect of octreotide and pasireotide

BiosciAbstracts